Objective To explore the efficacy and safety of autologous cell micrograft （ACM） extracts in the treatment of androgenetic alopecia （AGA）. Methods The situation of AGA patients receiving ACM extract injection treatment in alopecia region was retrospectively analyzed. The cell count， survival rate and cell subtypes of ACM extract suspensions were analyzed by flow cytometry. The patients were followed up for （12±2） weeks after treatment. The effectiveness of the treatment was comprehensively evaluated by the photos before and after treatment， dermoscopy images and patient satisfaction

questionnaire. At the same time， the injection area was observed for infection， swelling， rupture and other adverse reactions

to evaluate the safety of treatment. Results The study included 20 patients with AGA. The suspension of ACM extract contained up to 106 highly viable cells， with DPs comprising the majority. Treatment with ACM extract resulted in significant improvement in hair loss appearance and a notable increase in hair coverage （P<0.05）. Dermoscopic examination revealed a significant increase in overall hair density and a higher terminal-to-vellus hair ratio （T/V ratio）. Patient satisfaction was high， with reports of reduced scalp oiliness and itching post-treatment. Additionally， ACM extract treatment can improve depigmentation. None of the 20 patients experienced any treatment-related adverse reactions during follow-up. Conclusion　The application of ACM extract for the AGA treatment is safe and effective. This treatment method may serve as a novel approach to the AGA treatment as the injection of ACM extract was technologically simple and easy to use.

Autologous cell micrograft, Androgenetic alopecia, Hair regrowth, Dermal papilla cells, CD44